Candel Therapeutics, Inc. (CADL)
| Market Cap | 642.58M +166.7% |
| Revenue (ttm) | n/a |
| Net Income | -54.42M |
| EPS | -0.97 |
| Shares Out | 73.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,683,094 |
| Open | 8.67 |
| Previous Close | 8.91 |
| Day's Range | 7.78 - 9.07 |
| 52-Week Range | 4.35 - 9.27 |
| Beta | -0.59 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+116.65%) |
| Earnings Date | May 14, 2026 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 116.65% from the latest price.
News
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics Transcript: Study result
Extended follow-up from a phase III trial in intermediate to high-risk localized prostate cancer showed aglatimagene plus valacyclovir with radiotherapy significantly improved disease-free survival, reduced recurrence and metastasis rates, and was well-tolerated. Experts anticipate rapid adoption and a major shift in treatment options for this patient group.
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics to Present at Upcoming Investor Conferences
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth...
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologica...
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026
Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Candel Therapeutics (CADL) with an Overweight rating. The firm is highly bullish on Candel, arguing the stock is deeply undervalued based on a DCF suggesting…
Candel Therapeutics price target raised to $26 from $22 at Citi
Citi raised the firm’s price target on Candel Therapeutics (CADL) to $26 from $22 and keeps a Buy rating on the shares. The firm says the Phase 2a data for…
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
Candel Therapeutics (CADL) announced an additional 12 months of extended follow-up from its study of aglatimagene plus valacyclovir in combination with continued ICI therapy in patients with advanced ...
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
NEEDHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics price target lowered to $22 from $24 at Citi
Citi lowered the firm’s price target on Candel Therapeutics (CADL) to $22 from $24 and keeps a Buy rating on the shares. The firm says the company’s recent financings support…
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
“During the quarter we made meaningful progress across our clinical pipeline and pre-commercial readiness, entering 2026 with strong momentum and a robust set of potential value-driving catalysts,” sa...
Candel Therapeutics sees cash runway into 1Q28
Cash and cash equivalents, as of December 31, 2025, were $119.7 million compared to $102.7 million as of December 31, 2024. Based on current operating plans, the Company expects that…
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot...
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi...
Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Viral immunotherapies for solid tumors show strong clinical progress, with CAN-2409 achieving pivotal phase III success in prostate cancer and CAN-3110 demonstrating promising results in glioma. Regulatory submissions and new data are expected throughout 2024.
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
The deal range was $5.45-$5.65. LifeSci Capital acted as lead book running manager for the offering.
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
The deal range was $5.45-$5.65. LifeSci Capital acted as lead book running manager for the offering.
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
Candel Therapeutics announces $100M royalty funding agreement
Candel Therapeutics (CADL) announced a $100M royalty funding agreement with funds managed by RTW Investments, subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate ...
Candel Therapeutics announces $100M common stock offering
Candel Therapeutics (CADL) announced the launch of an underwritten public offering of $100M of its common stock. All shares of common stock to be sold in the offering will be…
Candel Therapeutics Announces Proposed $100 Million Public Offering
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...